Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Intravenous daratumumab is approved for the treatment of multiple myeloma. In part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and an efficacy simil...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haematologica
Glavni autori: San-Miguel, Jesus, Usmani, Saad Z., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Liu, Kevin, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L., Luo, Man, Farnsworth, Andrew, Nahi, Hareth, Chari, Ajai
Format: Artigo
Jezik:Inglês
Izdano: Fondazione Ferrata Storti 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168515/
https://ncbi.nlm.nih.gov/pubmed/32354874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.243790
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items